{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:20:10Z","timestamp":1791339610320,"version":"4.3.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Bladder cancer is a common malignancy in the United States and while the majority are non-muscle invasive at diagnosis, those with muscle-invasive and locally advanced disease can be challenging to manage. In addition, the prognosis is poorer in this group with high rates of recurrence following treatment. Clinical trials and advances in systemic therapy have helped to improve outcomes for these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials\/methods<\/jats:title>\n                    <jats:p>Articles were chosen for inclusion based on expert knowledge of the literature and PubMed literature searches for the relevant areas, with a focus on clinical trials. Appropriate articles were selected for inclusion by reviewing article titles, abstracts and full texts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The standard of care for treatment of muscle invasive bladder cancer involves neoadjuvant chemotherapy followed by radical cystectomy. The NIAGARA trial recently changed the standard of care to include immunotherapy both in the neoadjuvant and adjuvant settings. Multiple clinical trials have assessed the potential benefit of adjuvant immunotherapy in patients with high-risk disease after radical cystectomy, leading to the approval of nivolumab in this setting. Improvements in staging and surveillance of these patients are necessary. The use of circulating tumor DNA and advances in imaging have also shown promise in prognostication and detection and monitoring of recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Locally advanced bladder cancer is a challenging condition to manage, and while advances have been made in systemic therapy and biomarkers such as circulating tumor DNA, further investigation is needed to continue to improve outcomes for this group of patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-025-05960-3","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:45:31Z","timestamp":1759124731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of clinical stage T3\/T4 bladder cancer: a review"],"prefix":"10.1007","volume":"43","author":[{"given":"Domenique","family":"Escobar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Zahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"1","key":"5960_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5960_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/JU.0000000000003981","volume":"212","author":"J Holzbeierlein","year":"2017","unstructured":"Holzbeierlein J, Bixler BR, Buckley DI et al (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024. The Journal of urology 212(1):3\u201310. https:\/\/doi.org\/10.1097\/JU.0000000000003981","journal-title":"The Journal of urology"},{"issue":"2","key":"5960_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ucl.2013.01.003","volume":"40","author":"S Daneshmand","year":"2013","unstructured":"Daneshmand S (2013) Determining the role of cystectomy for high-grade T1 urothelial carcinoma. Urol Clin North Am 40(2):233\u2013247. https:\/\/doi.org\/10.1016\/j.ucl.2013.01.003","journal-title":"Urol Clin North Am"},{"issue":"3","key":"5960_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19(3):666\u2013675. https:\/\/doi.org\/10.1200\/JCO.2001.19.3.666","journal-title":"J Clin Oncol"},{"issue":"4","key":"5960_CR5","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.juro.2006.06.025","volume":"176","author":"PI Karakiewicz","year":"2006","unstructured":"Karakiewicz PI, Shariat SF, Palapattu GS et al (2006) Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 176(4):1354\u20131362. https:\/\/doi.org\/10.1016\/j.juro.2006.06.025","journal-title":"J Urol"},{"issue":"24","key":"5960_CR6","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1200\/jco.2005.05.3884","volume":"24","author":"Postoperative Nomogram Predicting Risk of Recurrence After Radical Cystectomy for Bladder Cancer","year":"2006","unstructured":"Postoperative Nomogram Predicting Risk of Recurrence After Radical Cystectomy for Bladder Cancer (2006) JCO 24(24):3967\u20133972. https:\/\/doi.org\/10.1200\/jco.2005.05.3884","journal-title":"JCO"},{"issue":"1","key":"5960_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3233\/BLC-150006","volume":"1","author":"AT Rozanski","year":"2015","unstructured":"Rozanski AT, Benson CR, McCoy JA et al (2015) Is exam under anesthesia still necessary for the staging of bladder cancer in the era of modern imaging? Bladder Cancer 1(1):91\u201396. https:\/\/doi.org\/10.3233\/BLC-150006","journal-title":"Bladder Cancer"},{"issue":"9","key":"5960_CR8","doi-asserted-by":"publisher","first-page":"390.e27","DOI":"10.1016\/j.urolonc.2023.04.001","volume":"41","author":"AK Czech","year":"2023","unstructured":"Czech AK, Gronostaj K, Fronczek J (2023) Diagnostic accuracy of bimanual palpation in bladder cancer patients undergoing cystectomy: a prospective study. Urol Oncol 41(9):390.e27-390.e33","journal-title":"Urol Oncol"},{"issue":"6","key":"5960_CR9","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.humpath.2006.01.027","volume":"37","author":"SS Shen","year":"2006","unstructured":"Shen SS, Lerner SP, Muezzinoglu B, Truong LD, Amiel G, Wheeler TM (2006) Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol 37(6):726\u2013734. https:\/\/doi.org\/10.1016\/j.humpath.2006.01.027","journal-title":"Hum Pathol"},{"issue":"5","key":"5960_CR10","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/MOU.0b013e32830b86f9","volume":"18","author":"SP Lerner","year":"2008","unstructured":"Lerner SP, Colen J, Shen S (2008) Prostatic biology, histologic patterns and clinical consequences of transitional cell carcinoma. Curr Opin Urol 18(5):508\u2013512. https:\/\/doi.org\/10.1097\/MOU.0b013e32830b86f9","journal-title":"Curr Opin Urol"},{"issue":"9","key":"5960_CR11","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/nejmoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349(9):859\u2013866. https:\/\/doi.org\/10.1056\/nejmoa022148","journal-title":"N Engl J Med"},{"issue":"16","key":"5960_CR12","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/jco.2010.32.3139","volume":"29","author":"International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, the Australian Bladder Cancer Study Group, the National Cancer Institute of Canada Clinical Trials Group","year":"2011","unstructured":"International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, the Australian Bladder Cancer Study Group, the National Cancer Institute of Canada Clinical Trials Group (2011) Finnbladder, Norwegian bladder cancer study Group, and club urologico Espanol de Tratamiento Oncologic. International phase III trial assessing neoadjuvant Cisplatin, Methotrexate, and vinblastine chemotherapy for Muscle-Invasive bladder cancer: Long-Term results of the BA06 30894 trial. JCO 29(16):2171\u20132177. https:\/\/doi.org\/10.1200\/jco.2010.32.3139","journal-title":"JCO"},{"issue":"9178","key":"5960_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(99)02292-8","volume":"354","author":"Neoadjuvant cisplatin","year":"1999","unstructured":"Neoadjuvant cisplatin (1999) methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 354(9178):533\u2013540","journal-title":"Lancet"},{"issue":"9","key":"5960_CR14","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-20-2409","volume":"27","author":"TW Flaig","year":"2021","unstructured":"Flaig TW, Tangen CM, Daneshmand S et al (2021) A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695). Clin Cancer Res 27(9):2435\u20132441. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2409","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5960_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s1470-2045(23)00587-9","volume":"25","author":"C Pfister","year":"2024","unstructured":"Pfister C, Gravis G, Flechon A (2024) Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol 25(2):255\u2013264. https:\/\/doi.org\/10.1016\/s1470-2045(23)00587-9","journal-title":"Lancet Oncol"},{"issue":"18","key":"5960_CR16","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.21.02051","volume":"40","author":"C Pfister","year":"2022","unstructured":"Pfister C, Gravis G, Fl\u00e9chon A et al (2022) Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial. J Clin Oncol 40(18):2013\u20132022. https:\/\/doi.org\/10.1200\/JCO.21.02051","journal-title":"J Clin Oncol"},{"issue":"6","key":"5960_CR17","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.juro.2017.12.062","volume":"199","author":"H Zargar","year":"2018","unstructured":"Zargar H, Shah JB, van Rhijn BW et al (2018) Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy. J Urol 199(6):1452\u20131458. https:\/\/doi.org\/10.1016\/j.juro.2017.12.062","journal-title":"J Urol"},{"issue":"3","key":"5960_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10147-023-02454-3","volume":"29","author":"DR Stormoen","year":"2024","unstructured":"Stormoen DR, Joensen UN, Daugaard G et al (2024) Glomerular filtration rate measurement during platinum treatment for urothelial carcinoma: optimal methods for clinical practice. Int J Clin Oncol 29(3):309\u2013317. https:\/\/doi.org\/10.1007\/s10147-023-02454-3","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"5960_CR19","doi-asserted-by":"publisher","first-page":"390","DOI":"10.4111\/icu.2020.61.4.390","volume":"61","author":"FL Carvalho","year":"2020","unstructured":"Carvalho FL, Zeymo A, Egan J et al (2020) Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer. Investig Clin Urol 61(4):390\u2013396. https:\/\/doi.org\/10.4111\/icu.2020.61.4.390","journal-title":"Investig Clin Urol"},{"issue":"12","key":"5960_CR20","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP et al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384(12):1125\u20131135. https:\/\/doi.org\/10.1056\/NEJMoa2035807","journal-title":"N Engl J Med"},{"issue":"10","key":"5960_CR21","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S et al (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390(10):875\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"issue":"16suppl","key":"5960_CR22","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1200\/jco.2024.42.16_suppl.4564","volume":"42","author":"PH O\u2019Donnell","year":"2024","unstructured":"O\u2019Donnell PH, Hoimes CJ, Rosenberg JE et al (2024) Study EV-103: neoadjuvant treatment with enfortumab Vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)\u20142-year event-free survival and safety data for cohort H. JCO 42(16suppl):4564\u20134564. https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.4564","journal-title":"JCO"},{"issue":"6suppl","key":"5960_CR23","doi-asserted-by":"publisher","first-page":"TPS585","DOI":"10.1200\/jco.2023.41.6_suppl.tps585","volume":"41","author":"A Necchi","year":"2023","unstructured":"Necchi A, Bedke J, Galsky MD et al (2023) Phase 3 KEYNOTE-905\/EV-303: perioperative pembrolizumab (pembro) or pembro\u2009+\u2009enfortumab Vedotin (EV) for muscle-invasive bladder cancer (MIBC). JCO 41(6suppl):TPS585\u2013TPS585. https:\/\/doi.org\/10.1200\/jco.2023.41.6_suppl.tps585","journal-title":"JCO"},{"issue":"6suppl","key":"5960_CR24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.6_suppl.tps588","volume":"41","author":"CJ Hoimes","year":"2023","unstructured":"Hoimes CJ, Loriot Y, Bedke J et al (2023) Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): phase 3 KEYNOTE-B15\/EV-304. JCO 41(6suppl):TPS588\u2013TPS588. https:\/\/doi.org\/10.1200\/jco.2023.41.6_suppl.tps588","journal-title":"JCO"},{"issue":"19","key":"5960_CR25","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/nejmoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD et al (2024) Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med 391(19):1773\u20131786. https:\/\/doi.org\/10.1056\/nejmoa2408154","journal-title":"N Engl J Med"},{"issue":"4","key":"5960_CR26","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.euf.2020.04.011","volume":"6","author":"S Daneshmand","year":"2020","unstructured":"Daneshmand S, Nazemi A (2020) Neoadjuvant chemotherapy in variant histology bladder cancer: current evidence. Eur Urol Focus 6(4):639\u2013641. https:\/\/doi.org\/10.1016\/j.euf.2020.04.011","journal-title":"Eur Urol Focus"},{"issue":"4","key":"5960_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.urolonc.2024.01.002","volume":"42","author":"I Cooke","year":"2024","unstructured":"Cooke I, Abou Heidar N, Mahmood AW et al (2024) The role of neoadjuvant chemotherapy for patients with variant histology muscle invasive bladder cancer undergoing robotic cystectomy: data from the international robotic cystectomy consortium. Urol Oncol 42(4):117. .e17-117.e25","journal-title":"Urol Oncol"},{"issue":"1","key":"5960_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/biomedicines13010086","volume":"13","author":"WA Kwon","year":"2025","unstructured":"Kwon WA, Seo HK, Song G, Lee MK, Park WS (2025) Advances in therapy for urothelial and non-urothelial subtype histologies of advanced bladder cancer: from etiology to current development. Biomedicines 13(1):86. https:\/\/doi.org\/10.3390\/biomedicines13010086","journal-title":"Biomedicines"},{"issue":"19","key":"5960_CR29","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T et al (2023) Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med 389(19):1778\u20131789. https:\/\/doi.org\/10.1056\/NEJMoa2309863","journal-title":"N Engl J Med"},{"issue":"13","key":"5960_CR30","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/nejmoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383(13):1218\u20131230. https:\/\/doi.org\/10.1056\/nejmoa2002788","journal-title":"N Engl J Med"},{"issue":"9","key":"5960_CR31","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.1007\/s00464-024-11074-5","volume":"38","author":"C You","year":"2024","unstructured":"You C, Cheng L, Fang Q et al (2024) Comparative evaluation of reproductive organ-preserving versus standard radical cystectomy in female: a meta-analysis and systematic review of perioperative, oncological, and functional outcomes. Surg Endosc 38(9):5041\u20135052. https:\/\/doi.org\/10.1007\/s00464-024-11074-5","journal-title":"Surg Endosc"},{"issue":"1","key":"5960_CR32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clgc.2021.11.005","volume":"20","author":"SH Patel","year":"2022","unstructured":"Patel SH, Wang S, Metcalf MR et al (2022) Safety and efficacy of reproductive organ-sparing radical cystectomy in women with variant histology and advanced stage. Clin Genitourin Cancer 20(1):60\u201368. https:\/\/doi.org\/10.1016\/j.clgc.2021.11.005","journal-title":"Clin Genitourin Cancer"},{"issue":"10139","key":"5960_CR33","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/S0140-6736(18)30996-6","volume":"391","author":"DJ Parekh","year":"2018","unstructured":"Parekh DJ, Reis IM, Castle EP (2018) Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet 391(10139):2525\u20132536. https:\/\/doi.org\/10.1016\/S0140-6736(18)30996-6","journal-title":"Lancet"},{"issue":"6","key":"5960_CR34","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.clgc.2021.07.006","volume":"19","author":"AG Reddy","year":"2021","unstructured":"Reddy AG, Sparks AD, Darwish C, Whalen MJ (2021) Oncologic outcomes for robotic vs. open radical cystectomy among locally advanced and node-positive patients: analysis of the National Cancer Database. Clin Genitourin Cancer 19(6):547\u2013553. https:\/\/doi.org\/10.1016\/j.clgc.2021.07.006","journal-title":"Clin Genitourin Cancer"},{"issue":"21","key":"5960_CR35","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1001\/jama.2022.7393","volume":"327","author":"JWF Catto","year":"2022","unstructured":"Catto JWF, Khetrapal P, Ricciardi F et al (2022) Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: a randomized clinical trial. JAMA 327(21):2092\u20132103. https:\/\/doi.org\/10.1001\/jama.2022.7393","journal-title":"JAMA"},{"issue":"2","key":"5960_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/jjco\/hyaa168","volume":"51","author":"K Hakozaki","year":"2021","unstructured":"Hakozaki K, Kikuchi E, Ogihara K et al (2021) Significance of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer. Jpn J Clin Oncol 51(2):287\u2013295. https:\/\/doi.org\/10.1093\/jjco\/hyaa168","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"5960_CR37","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.juro.2008.07.039","volume":"180","author":"JL Nelles","year":"2008","unstructured":"Nelles JL, Konety BR, Saigal C, Pace J, Lai J (2008) Urologic diseases in America Project. Urethrectomy following cystectomy for bladder cancer in men: practice patterns and impact on survival. J Urol 180(5):1933\u20131936 discussion 1936\u20131937. https:\/\/doi.org\/10.1016\/j.juro.2008.07.039","journal-title":"J Urol"},{"issue":"2","key":"5960_CR38","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1097\/JS9.0000000000000904","volume":"110","author":"J Yu","year":"2024","unstructured":"Yu J, Lee CU, Chung JH et al (2024) Impact of urinary diversion type on urethral recurrence following radical cystectomy for bladder cancer: propensity score matched and weighted analyses of retrospective cohort. Int J Surg 110(2):700\u2013708. https:\/\/doi.org\/10.1097\/JS9.0000000000000904","journal-title":"Int J Surg"},{"issue":"3","key":"5960_CR39","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s11255-013-0461-8","volume":"45","author":"E Brunocilla","year":"2013","unstructured":"Brunocilla E, Pernetti R, Schiavina R et al (2013) The number of nodes removed as well as the template of the dissection is independently correlated to cancer-specific survival after radical cystectomy for muscle-invasive bladder cancer. Int Urol Nephrol 45(3):711\u2013719. https:\/\/doi.org\/10.1007\/s11255-013-0461-8","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"5960_CR40","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.eururo.2018.09.047","volume":"75","author":"JE Gschwend","year":"2019","unstructured":"Gschwend JE, Heck MM, Lehmann J (2019) Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial. Eur Urol 75(4):604\u2013611. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.047","journal-title":"Eur Urol"},{"issue":"13","key":"5960_CR41","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa2401497","volume":"391","author":"SP Lerner","year":"2024","unstructured":"Lerner SP, Tangen C, Svatek RS et al (2024) Standard or extended lymphadenectomy for muscle-invasive bladder cancer. N Engl J Med 391(13):1206\u20131216. https:\/\/doi.org\/10.1056\/NEJMoa2401497","journal-title":"N Engl J Med"},{"issue":"6","key":"5960_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/iju.70022","volume":"32","author":"M Zahir","year":"2025","unstructured":"Zahir M, Doshi C, Escobar D, Daneshmand S (2025) Bladder preservation: an overview of novel prospects and limitations. Int J Urol iju70022. https:\/\/doi.org\/10.1111\/iju.70022","journal-title":"Int J Urol"},{"key":"5960_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.03.017","author":"S Gupta","year":"2025","unstructured":"Gupta S, Hensley PJ, Li R et al (2025) Bladder preservation strategies in muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. European urology. https:\/\/doi.org\/10.1016\/j.eururo.2025.03.017","journal-title":"European urology"},{"issue":"6","key":"5960_CR44","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta AR, Ballas LK, Niemierko A et al (2023) Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol 24(6):669\u2013681. https:\/\/doi.org\/10.1016\/S1470-2045(23)00170-5","journal-title":"Lancet Oncol"},{"issue":"16suppl","key":"5960_CR45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e16603","volume":"42","author":"JD Mackey","year":"2024","unstructured":"Mackey JD, Atieh K (2024) Chemoradiation versus cystectomy for locally advanced bladder cancer: a global, propensity-matched retrospective cohort study. JCO 42(16suppl):e16603. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e16603","journal-title":"JCO"},{"key":"5960_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100866","volume":"49","author":"P Carriere","year":"2024","unstructured":"Carriere P, Alhalabi O, Gao J et al (2024) Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clin Transl Radiat Oncol 49:100866. https:\/\/doi.org\/10.1016\/j.ctro.2024.100866","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"5960_CR47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.eururo.2016.12.002","volume":"72","author":"RE Krasnow","year":"2017","unstructured":"Krasnow RE, Drumm M, Roberts HJ et al (2017) Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy. Eur Urol 72(1):54\u201360. https:\/\/doi.org\/10.1016\/j.eururo.2016.12.002","journal-title":"Eur Urol"},{"issue":"4","key":"5960_CR48","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt J, Hussain M, Gschwend JE et al (2021) Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22(4):525\u2013537. https:\/\/doi.org\/10.1016\/S1470-2045(21)00004-8","journal-title":"Lancet Oncol"},{"issue":"4","key":"5960_CR49","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1464-410X.2010.09912.x","volume":"108","author":"FA Yafi","year":"2011","unstructured":"Yafi FA, Aprikian AG, Chin JL et al (2011) Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int 108(4):539\u2013545. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09912.x","journal-title":"BJU Int"},{"issue":"3","key":"5960_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11912-019-0772-8","volume":"21","author":"JT Matulay","year":"2019","unstructured":"Matulay JT, Narayan VM, Kamat AM (2019) Clinical and genomic considerations for variant histology in bladder cancer. Curr Oncol Rep 21(3):23. https:\/\/doi.org\/10.1007\/s11912-019-0772-8","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"5960_CR51","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","volume":"81","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group","year":"2022","unstructured":"Advanced Bladder Cancer (ABC) Meta-analysis Collaborators Group (2022) Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials. Eur Urol 81(1):50\u201361. https:\/\/doi.org\/10.1016\/j.eururo.2021.09.028","journal-title":"Eur Urol"},{"issue":"22","key":"5960_CR52","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE et al (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 384(22):2102\u20132114. https:\/\/doi.org\/10.1056\/NEJMoa2034442","journal-title":"N Engl J Med"},{"issue":"1","key":"5960_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"AB Apolo","year":"2025","unstructured":"Apolo AB, Ballman KV, Sonpavde G et al (2025) Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N Engl J Med 392(1):45\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2401726","journal-title":"N Engl J Med"},{"issue":"1","key":"5960_CR54","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12935-025-03707-z","volume":"25","author":"X Gao","year":"2025","unstructured":"Gao X, Qi W, Li J et al (2025) Prognostic and predictive role of circulating tumor DNA detection in patients with muscle invasive bladder cancer: a systematic review and meta-analysis. Cancer Cell Int 25(1):75. https:\/\/doi.org\/10.1186\/s12935-025-03707-z","journal-title":"Cancer Cell Int"},{"issue":"7","key":"5960_CR55","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2217\/fon-2022-0868","volume":"19","author":"F Jackson-Spence","year":"2023","unstructured":"Jackson-Spence F, Toms C, O\u2019Mahony LF et al (2023) IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA\u2009+\u2009post-surgery. Future Oncol 19(7):509\u2013515. https:\/\/doi.org\/10.2217\/fon-2022-0868","journal-title":"Future Oncol"},{"issue":"20","key":"5960_CR56","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/JCO.23.01983","volume":"42","author":"N Kl\u00fcmper","year":"2024","unstructured":"Kl\u00fcmper N, Tran NK, Zsch\u00e4bitz S et al (2024) Nectin4 amplification is frequent in solid tumors and predicts enfortumab Vedotin response in metastatic urothelial cancer. J Clin Oncol 42(20):2446\u20132455. https:\/\/doi.org\/10.1200\/JCO.23.01983","journal-title":"J Clin Oncol"},{"issue":"3","key":"5960_CR57","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.urolonc.2015.08.018","volume":"34","author":"S Rais-Bahrami","year":"2016","unstructured":"Rais-Bahrami S, Pietryga JA, Nix JW (2016) Contemporary role of advanced imaging for bladder cancer staging. Urologic Oncology: Seminars Original Investigations 34(3):124\u2013133. https:\/\/doi.org\/10.1016\/j.urolonc.2015.08.018","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"issue":"11","key":"5960_CR58","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.urolonc.2021.04.024","volume":"39","author":"AC Civelek","year":"2021","unstructured":"Civelek AC, Niglio SA, Malayeri AA et al (2021) Clinical value of 18FDG PET\/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer. Urol Oncol 39(11):787. .e17-787.e21","journal-title":"Urol Oncol"},{"issue":"2","key":"5960_CR59","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2967\/jnumed.123.266390","volume":"65","author":"VS Koshkin","year":"2024","unstructured":"Koshkin VS, Kumar V, Kline B et al (2024) Initial experience with 68Ga-FAP-2286 PET imaging in patients with urothelial cancer. J Nucl Med 65(2):199\u2013205. https:\/\/doi.org\/10.2967\/jnumed.123.266390","journal-title":"J Nucl Med"},{"issue":"5","key":"5960_CR60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40134-023-00412-5","volume":"11","author":"L Eusebi","year":"2023","unstructured":"Eusebi L, Masino F, Gifuni R et al (2023) Role of multiparametric-MRI in bladder cancer. Curr Radiol Rep 11(5):69\u201380. https:\/\/doi.org\/10.1007\/s40134-023-00412-5","journal-title":"Curr Radiol Rep"},{"issue":"3","key":"5960_CR61","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","volume":"74","author":"V Panebianco","year":"2018","unstructured":"Panebianco V, Narumi Y, Altun E et al (2018) Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical imaging-Reporting and data System). Eur Urol 74(3):294\u2013306. https:\/\/doi.org\/10.1016\/j.eururo.2018.04.029","journal-title":"Eur Urol"},{"issue":"1","key":"5960_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010038","volume":"14","author":"JW van Hattum","year":"2021","unstructured":"van Hattum JW, de Ruiter BM, Oddens JR, Hulshof MCCM, de Reijke TM, Bins AD (2021) Bladder-sparing chemoradiotherapy combined with immune checkpoint inhibition for locally advanced urothelial bladder cancer-a review. Cancers (Basel) 14(1):38. https:\/\/doi.org\/10.3390\/cancers14010038","journal-title":"Cancers (Basel)"},{"key":"5960_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.04.008","author":"CE Chu","year":"2025","unstructured":"Chu CE, Chen Z, Whiting K et al (2025) Clinical outcomes, genomic heterogeneity, and therapeutic considerations across histologic subtypes of urothelial carcinoma. European Urology. https:\/\/doi.org\/10.1016\/j.eururo.2025.04.008","journal-title":"European Urology"},{"issue":"12","key":"5960_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111859","volume":"41","author":"TN Clinton","year":"2022","unstructured":"Clinton TN, Chen Z, Wise H (2022) Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell Rep 41(12):111859. https:\/\/doi.org\/10.1016\/j.celrep.2022.111859","journal-title":"Cell Rep"},{"key":"5960_CR65","unstructured":"IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera\u2122 Strongly Predicting Adjuvant Immunotherapy Benefit. Natera, Inc. https:\/\/www.natera.com\/company\/news\/imvigor011-bladder-cancer-trial-achieves-positive-results-with-signatera-strongly-predicting-adjuvant-immunotherapy-benefit\/"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05960-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05960-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05960-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:03:54Z","timestamp":1767996234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05960-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5960"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05960-3","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"583"}}